These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 12044803)
1. Evaluation of the effects of anti-thromboxane agents in platelet-vessel wall interaction. Buccellati C; Ciceri P; Ballerio R; Casagrande C; Folco G; Nicosia S Eur J Pharmacol; 2002 May; 443(1-3):133-41. PubMed ID: 12044803 [TBL] [Abstract][Full Text] [Related]
2. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets. Berrettini M; De Cunto M; Parise P; Grasselli S; Nenci GG Eur J Clin Pharmacol; 1990; 39(5):495-500. PubMed ID: 1963845 [TBL] [Abstract][Full Text] [Related]
3. Endothelium-dependent contraction induced by acetylcholine in isolated rat renal arteries. Nishimura Y; Usui H; Kurahashi K; Suzuki A Eur J Pharmacol; 1995 Mar; 275(2):217-21. PubMed ID: 7796858 [TBL] [Abstract][Full Text] [Related]
5. Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe. Komiotis D; Wencel-Drake JD; Dieter JP; Lim CT; Le Breton GC Biochem Pharmacol; 1996 Sep; 52(5):763-70. PubMed ID: 8765474 [TBL] [Abstract][Full Text] [Related]
6. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Gresele P; Deckmyn H; Arnout J; Nenci GG; Vermylen J Thromb Haemost; 1989 Jun; 61(3):479-84. PubMed ID: 2552606 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor. Yu SM; Wu TS; Teng CM Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of 2NTX-99 [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a potential antiatherothrombotic agent with antithromboxane and nitric oxide donor activity in platelet and vascular preparations. Buccellati C; Sala A; Rossoni G; Capra V; Rovati GE; Di Gennaro A; Folco G; Colli S; Casagrande C J Pharmacol Exp Ther; 2006 May; 317(2):830-7. PubMed ID: 16399881 [TBL] [Abstract][Full Text] [Related]
9. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. Cattaneo M; Tenconi PM; Lecchi A; Mannucci PM Thromb Res; 1991 Jun; 62(6):717-24. PubMed ID: 1926062 [TBL] [Abstract][Full Text] [Related]
10. [In vitro study of the mechanism of the platelet anti-aggregant action of picotamide (G 137)]. Berrettini M; De Cunto M; Romanelli A; Volpato I; Orzalesi G; Nenci GG Boll Soc Ital Biol Sper; 1983 Mar; 59(3):309-15. PubMed ID: 9704127 [No Abstract] [Full Text] [Related]
11. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion. Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016 [TBL] [Abstract][Full Text] [Related]
12. Stretch-induced contraction of rabbit isolated pulmonary artery and the involvement of endothelium-derived thromboxane A2. Nakayama K; Ueta K; Tanaka Y; Tanabe Y; Ishii K Br J Pharmacol; 1997 Sep; 122(2):199-208. PubMed ID: 9313926 [TBL] [Abstract][Full Text] [Related]
13. Inhibition by picotamide of thromboxane production in vitro and ex vivo. Violi F; Ghiselli A; Iuliano L; Praticò D; Alessandri C; Balsano F Eur J Clin Pharmacol; 1988; 33(6):599-602. PubMed ID: 3366163 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552. Harris DN; Michel IM; Goldenberg HJ; Hartl KS; Allen GT; Steinbacher TE; Schumacher WA; Han WC; Hall SE; Floyd DM J Pharmacol Exp Ther; 1992 Apr; 261(1):131-7. PubMed ID: 1532833 [TBL] [Abstract][Full Text] [Related]
15. HA-29: an inhibitor of thromboxane A2 formation with antagonism of thromboxane A2/prostaglandin endoperoxide receptor in rabbit platelets. Lin CH; Kuo SC; Huang LJ; Huang TF; Teng CM Thromb Res; 1992 Apr; 66(1):61-73. PubMed ID: 1412184 [TBL] [Abstract][Full Text] [Related]
16. Antiaggregatory effects of thromboxane receptor antagonists in vivo. Darius H; Lefer AM Thromb Res; 1985 Dec; 40(5):663-75. PubMed ID: 2935972 [TBL] [Abstract][Full Text] [Related]
17. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro. O'Keefe EH; Liu EC; Greenberg R; Ogletree ML Prostaglandins; 1985 May; 29(5):785-97. PubMed ID: 3925501 [TBL] [Abstract][Full Text] [Related]
18. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo. Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161 [TBL] [Abstract][Full Text] [Related]
19. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction. De La Cruz JP; Villalobos MA; Escalante R; Guerrero A; Arrebola MM; Sánchez de La Cuesta F Br J Pharmacol; 2002 Dec; 137(7):1082-8. PubMed ID: 12429581 [TBL] [Abstract][Full Text] [Related]
20. Binding and function of a potent new thromboxane receptor antagonist, BMS 180,291, in human platelets. Webb ML; Liu EC; Monshizadegan H; Hedberg A; Misra RN; Goldenberg H; Harris DN J Pharmacol Exp Ther; 1993 Mar; 264(3):1387-94. PubMed ID: 8450473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]